Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease
Bradley J RobottomDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD, USAAbstract: Parkinson's disease (PD) is the second most common neurodegenerative disease and the most treatable. Treatment of PD is symptomatic and generally focuses on the replacement o...
Main Author: | Bradley J Robottom |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-01-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/efficacy-safety-and-patient-preference-of-monoamine-oxidase-b-inhibito-a6098 |
Similar Items
-
Inhibitors of monoamine oxidase
by: Mullan, Elaine L.
Published: (1996) -
Identification of novel scaffolds for Monoamine oxidase B inhibitors
by: Odhar, Hasanain
Published: (2014) -
Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
by: Reichmann Heinz, et al.
Published: (2011-09-01) -
Amphetamine Derivatives as Monoamine Oxidase Inhibitors
by: Miguel Reyes-Parada, et al.
Published: (2020-01-01) -
3-Coumaranone derivatives as inhibitors of monoamine oxidase
by: Van Dyk AS, et al.
Published: (2015-10-01)